25 August 2025 – Sydney, Australia | LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) today announced highly encouraging results from a case series that is evaluating the efficacy of its intranasal erectile dysfunction therapy, SPONTAN®, in men recovering from radical prostatectomy.
The results, presented at the 25th Asia-Pacific Prostate Cancer Conference (APCC) in Sydney, showed 100% patient satisfaction among participants of the study, with all patients preferring SPONTAN over conventional oral tablet ED treatments, due to its spontaneity, ease of use, and more rapid onset of effects.
HIGHLIGHTS
-
100% patient satisfaction reported across all participants in post-prostatectomy study.
-
All patients preferred SPONTAN® over traditional oral therapies for erectile dysfunction.
-
Spontaneity and ease of use were highlighted as major benefits among patients.
-
A large underserved market exists, with ~8,500 radical prostatectomies performed annually in Australia and hundreds of thousands globally.
-
Data presented at APCC, Asia-Pacific’s leading prostate cancer research forum.
Erectile dysfunction (ED) remains one of the most common long-term side effects following a radical prostatectomy procedure (removal of the prostate gland and seminal vesicles), with oral PDE5 treatments failing to deliver adequate outcomes for many patients. Studies suggest up to 50% of men discontinue oral ED treatments due to lack of spontaneity and tolerability.
SPONTAN’s differentiated intranasal delivery mechanism offers a potential first-line therapeutic alternative for this significant and underserved patient population.
LTR Pharma’s Executive Chairman, Lee Rodne, stated: "These real-world clinical outcomes confirm that SPONTAN has the potential to transform treatment for prostate cancer survivors suffering from erectile dysfunction, a population where current therapies routinely fail. The fact that all patients in this independent case series not only achieved therapeutic success but also actively preferred our nasal spray technology over conventional treatments is tremendously encouraging. With a significant and growing global market of post-prostatectomy patients, these results strengthen our conviction that SPONTAN is positioned to become the first-line therapy in this underserved population, unlocking major commercial potential for LTR Pharma.”
Next Steps
The positive case series further builds LTR Pharma’s clinical validation package and supports the advancement of SPONTAN through late-stage regulatory pathways in Australia, the U.S., and other key global markets.
SPONTAN is currently available in Australia through the Therapeutic Goods Administration’s (TGA) Special Access Scheme, while LTR Pharma is also preparing to introduce ROXUS, a variation of SPONTAN, into the U.S. market under the personalised healthcare pathway.
About us:
About LTR Pharma Limited (ASX:LTP)
LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies for significant unmet medical needs through its proprietary intranasal drug delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets.
LTR’s lead products, SPONTAN® and ROXUS® , are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW®, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.
Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.
Contact details:
Jane Morgan
Jane Morgan Management
Investor & Media Relations
[email protected]
